指南与共识主动脉疾病

编者推荐——欧洲血管外科学会(ESVS)腹主动脉瘤临床实践指南中关于接受Nellix腔内动脉瘤封闭(EVAS)系统治疗患者的聚焦更新

Editor's Choice - Focused Update on Patients Treated with the Nellix EndoVascular Aneurysm Sealing (EVAS) System from the European Society for Vascular Surgery (ESVS) Abdominal Aortic Aneurysm Clinical Practice Guidelines.
指南 / 共识 · Eur J Vasc Endovasc Surg · 2023-01-07

欧洲血管外科学会(ESVS)腹主动脉瘤(AAA)临床实践指南编写委员会基于范围综述,针对植入Nellix腔内动脉瘤封闭(EVAS)装置患者的监测与管理提出推荐,推荐按欧洲心脏病学会(ESC)分级系统分级。EVAS后晚期内移植物迁移导致近端1型内漏及破裂风险很高,需开放转换与装置取出;择期取出 reported 死亡率为0%至14%,而因破裂急诊转换预后极差,死亡率为67%至75%。推荐所有植入Nellix装置的患者均应被识别、充分告知并纳入强化监测;若发现装置失败,对手术适合的患者应考虑早期择期装置取出。

要点

  • 所有植入Nellix装置的患者均应被识别、充分告知并纳入强化监测。
  • EVAS后晚期内移植物迁移致近端1型内漏及破裂风险很高,需开放转换与装置取出。
  • 择期装置取出死亡率为0%至14%,破裂急诊转换死亡率为67%至75%。

核心结论

  • 推荐所有植入Nellix装置的患者均应被识别、充分告知并纳入强化监测。
  • 若发现装置失败,对手术适合的患者应考虑早期择期装置取出。

研究设计与样本

  • 欧洲血管外科学会(ESVS)腹主动脉瘤(AAA)临床实践指南编写委员会基于对接受EVAS治疗AAA患者晚期严重主动脉相关不良事件风险的范围综述,达成按欧洲心脏病学会(ESC)分级系统分级的推荐。

主要发现

  • EVAS后晚期内移植物迁移导致近端1型内漏及破裂风险的发生率很高,需开放转换与装置取出。
  • 择期装置取出的 reported 死亡率在0%至14%之间。
  • 因破裂急诊转换预后极差,死亡率为67%至75%。

关键数值与推荐

  • 推荐所有植入Nellix装置的患者均应被识别、充分告知并纳入强化监测(推荐按ESC分级系统分级)。
  • 若发现装置失败,对手术适合的患者应考虑早期择期装置取出(推荐按ESC分级系统分级)。

临床怎么用

  • 对所有植入Nellix装置的患者进行识别、充分告知并纳入强化监测。
  • 若发现装置失败,对手术适合的患者考虑早期择期装置取出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: After alerts on EndoVascular Aneurysm Seal (EVAS) failure were raised, the European Society for Vascular Surgery (ESVS) Abdominal Aortic Aneurysm (AAA) Clinical Practice Guidelines Writing Committee (WC) initiated a task force with the aim to provide guidance on surveillance and management of patients with implanted EVAS devices. METHODS: Based on a scoping review of risk for late serious aortic-related adverse events in patients treated with EVAS for AAA, the ESVS AAA Guidelines WC agreed on recommendations graded according to the European Society of Cardiology (ESC) grading system. RESULTS: EVAS has a very high incidence of late endograft migration resulting in proximal type 1 endoleak with risk of rupture, requiring open conversion with device explantation. The reported mortality rate for elective explantation varies between 0% and 14%, while acute conversion for rupture has a very dismal prognosis with a 67 - 75% mortality rate. CONCLUSION: It is recommended that all patients in whom a Nellix device has been implanted should be identified, properly informed, and enrolled in enhanced surveillance. If device failure is detected, early elective device explantation should be considered in surgically fit patients.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Boyle JR, Tsilimparis N, Van Herzeele I, et al. Editor's Choice - Focused Update on Patients Treated with the Nellix EndoVascular Aneurysm Sealing (EVAS) System from the European Society for Vascular Surgery (ESVS) Abdominal Aortic Aneurysm Clinical Practice Guidelines. Eur J Vasc Endovasc Surg. 2023. PMID: 36623763. doi:10.1016/j.ejvs.2022.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。